• Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME)
• Remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual acuity compared with anti-VEGF therapy in a pivotal DME trial
• Despite available therapies, up to 40% of people with DME have persistent disease after six months, driving need for new approaches

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.